chimeric natriuretic peptide

Peptideexperimental

Cenderitide is a natriuretic peptide developed by the Mayo Clinic as a potential treatment for heart failure. Cenderitide is created by the fusion of the 15 amino acid C-terminus of the snake venom dendroaspis natriuretic peptide (DNP) with the full C-type natriuretic peptide (CNP) structure. This peptide chimera is a dual activator of the natriuretic peptide receptors NPR-A and NPR-B and therefore exhibits the natriuretic and diuretic properties of DNP, as well as the antiproliferative and antifibrotic properties of CNP. — Wikipedia

Clinical trial activity

8 trials · 5 clinical orgs · 0 marketing orgs

Phase 1
6
Phase 2
2
Phase 3
0
Phase 4
0

Earliest trial started Jan 1, 2007 (NCT00482937)

Timeline

2000s

  1. Jan 1, 2007

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2008

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • chimeric natriuretic peptide

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT01407900Phase 1Jan 1, 2014Mayo Clinic, National Institutes of Health (NIH)
NCT02071602Phase 1Oct 1, 2013Mayo Clinic
NCT01750905Phase 1Apr 1, 2013Mayo Clinic
NCT00839007Phase 2Jun 1, 2009Nile Therapeutics
NCT00699712Phase 2Jun 1, 2008Momentum Research, Inc., Nile Therapeutics
NCT00620308Phase 1Jun 1, 2008Mayo Clinic
NCT00557661Phase 1Nov 1, 2007Hennepin Healthcare, Nile Therapeutics
NCT00482937Phase 1Jan 1, 2007Nile Therapeutics
Showing 8 of 8 trials
Page 1 / 1

Organizations

Research & Development (5)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Mayo ClinicAcademic/Hospital4412008
Nile TherapeuticsFor profit4422007
Hennepin HealthcareAcademic/Hospital1012007
Momentum Research, Inc.For profit1012008
National Institutes of Health (NIH)Government1012014
5 organizations
Page 1 / 1